Journal of Clinical Oncology, Vol 5, 2032-2040, Copyright © 1987 by American Society of Clinical Oncology

ARTICLES

Trimetrexate: a second generation folate antagonist in clinical trial

JT Lin and JR Bertino
Department of Medicine, Yale University School of Medicine, New Haven, CT.

Trimetrexate is a promising new lipophilic antifolate with antitumor and antimicrobial activity, which is currently undergoing clinical trials. It differs from methotrexate in its transport and intracellular retention, and may be useful against tumors resistant to methotrexate because of impaired transport or deficient polyglutamylation. In preclinical studies, it has demonstrated a broader spectrum of antitumor activity than methotrexate, and appears to have synergistic antitumor activity when combined with a number of other agents. In clinical trials, the primary toxicity has been hematologic, with rapid recovery and no evidence of cumulative dose effect. Nonhematologic toxicity has been sporadic. Preliminary results of phase II trials indicate activity against breast, non-small-cell lung, and head and neck tumors. In addition, trimetrexate with simultaneous leucovorin rescue appears to be a promising new treatment for pneumocystis pneumonia in AIDS patients, with minimal toxic side effects.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Yang, E. A. Kolb, J. Qin, A. Chou, R. Sowers, B. Hoang, J. H. Healey, A. G. Huvos, P. A. Meyers, and R. Gorlick The Folate Receptor {alpha} Is Frequently Overexpressed in Osteosarcoma Samples and Plays a Role in the Uptake of the Physiologic Substrate 5-Methyltetrahydrofolate Clin. Cancer Res., May 1, 2007; 13(9): 2557 - 2567. [Abstract] [Full Text] [PDF]

				C. L. Sweeney, M. D. Diers, J. L. Frandsen, R. Gunther, C. M. Verfaillie, and R. S. McIvor Methotrexate Exacerbates Tumor Progression in a Murine Model of Chronic Myeloid Leukemia J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1075 - 1084. [Abstract] [Full Text] [PDF]

				M. G. Rots, R. Pieters, G. J. Peters, C. H. van Zantwijk, R. Mauritz, P. Noordhuis, J. C. Willey, K. Hahlen, U. Creutzig, G. Janka-Schaub, et al. Circumvention of Methotrexate Resistance in Childhood Leukemia Subtypes by Rationally Designed Antifolates Blood, November 1, 1999; 94(9): 3121 - 3128. [Abstract] [Full Text] [PDF]

				J.R. Bertino, E. Goker, R. Gorlick, W.W. Li, and D. Banerjee Resistance Mechanisms to Methotrexate in Tumors Oncologist, August 1, 1996; 1(4): 223 - 226. [Abstract] [Full Text] [PDF]

				H. Sprecher, H. M. Barr, J. I. Slotky, M. Tzukerman, G. D. Eytan, and Y. G. Assaraf Alteration of Mitochondrial Gene Expression and Disruption of Respiratory Function by the Lipophilic Antifolate Pyrimethamine in Mammalian Cells J. Biol. Chem., September 1, 1995; 270(35): 20668 - 20676. [Abstract] [Full Text] [PDF]